Technology evaluation: CpG-7909, Coley.
Coley Pharmaceutical (formerly CpG ImmunoPharmaceuticals) is developing CpG-7909 (ProMune) for use in the potential treatment of cancer and as a vaccine adjuvant. By April 2000, CpG-7909 had entered phase I/II trials for cancer and in March 2002, Coley initiated a phase I trial in non-Hodgkin's lymphoma in combination with rituximab (Rituxan). By October 2002, CpG-7909 was in phase II trials as a vaccine adjuvant. Cpg-7909 is currently also undergoing phase II trials for melanoma.
Paul
Stéphane
S
Transgene SA, 2 Rue Adolphe Hirn, Strasbourg 67082, France. paul@transgene.fr
D000276:Adjuvants, Immunologic / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D018899:CpG Islands; D004268:DNA-Binding Proteins / Q000276:immunology / Q000378:metabolism; D006509:Hepatitis B / Q000188:drug therapy; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D009838:Oligodeoxyribonucleotides / Q000493:pharmacokinetics / Q000627:therapeutic use*; D020319:Oligodeoxyribonucleotides, Antisense / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000276:immunology / Q000378:metabolism; D051217:Toll-Like Receptor 9
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; D009838:Oligodeoxyribonucleotides; D020319:Oligodeoxyribonucleotides, Antisense; C483020:ProMune; D011956:Receptors, Cell Surface; C495371:TLR9 protein, human; D051217:Toll-Like Receptor 9